Literature DB >> 25393251

Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.

Melissa Pulitzer1, Patricia L Myskowski, Steven M Horwitz, Christiane Querfeld, Brian Connolly, Janet Li, Rajmohan Murali.   

Abstract

Large cell transformation of mycosis fungoides (MF-LCT) occurs in 20-50% of advanced MF, and is generally associated with poor prognosis, although some patients have indolent disease. We sought to identify clinicopathological prognostic factors in a large number of patients with MF-LCT.We identified patients with MF-LCT treated between 1991 and 2012 at a referral centre for cutaneous lymphoma. Clinical and pathological records, and histopathological slides were reviewed. Associations of clinicopathological variables with disease-specific survival were analysed.In 51 patients with MF-LCT, factors significantly associated with shorter survival were: age >60 years (25 versus 61  months, p = 0.01), stage III/IV (25 versus 44  months, p = 0.049), high serum lactate dehydrogenase (LDH; 24 versus 53  months, p = 0.007), absent papillary dermal involvement (8 versus 30  months, p = 0.008); follicular mucin at transformation (24 versus 42  months, p = 0.007); and the absence of fibrosis at transformation (21 versus 42  months, p = 0.03). Patients presenting with transformation at diagnosis had better survival than those who started with a small cell phenotype (p = 0.02). Age >60 years was independently associated with poorer survival (HR 5.61, 95%CI 1.17-26.8, p = 0.03), and the presence of fibrosis at transformation was independently associated with improved survival (HR 0.30, 95%CI 0.09-0.97, p = 0.045).In patients with MF-LCT, clinical features (age, stage, serum LDH) are important in assessing prognosis. Additional clinical and pathological features identified in this study may also assist in prognostic stratification. Studies of larger cohorts should be performed to validate the prognostic significance of these features.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25393251      PMCID: PMC5042322          DOI: 10.1097/PAT.0000000000000166

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  27 in total

1.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.

Authors:  H S Zackheim; S Amin; M Kashani-Sabet; A McMillan
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

2.  Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma.

Authors:  L Cerroni; E Rieger; S Hödl; H Kerl
Journal:  Am J Surg Pathol       Date:  1992-06       Impact factor: 6.394

3.  Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates.

Authors:  R Dummer; S A Michie; D Kell; J W Gould; A C Haeffner; B R Smoller; R A Warnke; G S Wood
Journal:  J Cutan Pathol       Date:  1995-02       Impact factor: 1.587

4.  Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study.

Authors:  K E Salhany; J B Cousar; J P Greer; T T Casey; J P Fields; R D Collins
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

5.  Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders.

Authors:  Thilo Gambichler; Stefan Bischoff; Falk G Bechara; Peter Altmeyer; Alexander Kreuter
Journal:  J Dermatol Sci       Date:  2007-09-10       Impact factor: 4.563

6.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

Authors:  E Diamandidou; M Colome-Grimmer; L Fayad; M Duvic; R Kurzrock
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

7.  Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.

Authors:  Kelley A Vidulich; Rakhshandra Talpur; Roland L Bassett; Madeleine Duvic
Journal:  Int J Dermatol       Date:  2009-03       Impact factor: 2.736

8.  Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.

Authors:  E Dmitrovsky; M J Matthews; P A Bunn; G P Schechter; R W Makuch; C F Winkler; J Eddy; E A Sausville; D C Ihde
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

9.  Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation.

Authors:  Suzanne O Arulogun; H Miles Prince; Jonathan Ng; Stephen Lade; Gail F Ryan; Odette Blewitt; Christopher McCormack
Journal:  Blood       Date:  2008-07-22       Impact factor: 22.113

10.  Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

Authors:  Vincent D Criscione; Martin A Weinstock
Journal:  Arch Dermatol       Date:  2007-07
View more
  10 in total

Review 1.  Cutaneous T-cell Lymphoma.

Authors:  Melissa Pulitzer
Journal:  Clin Lab Med       Date:  2017-09       Impact factor: 1.935

2.  Unusual variants of mycosis fungoides.

Authors:  Pooja Virmani; Patricia L Myskowski; Melissa Pulitzer
Journal:  Diagn Histopathol (Oxf)       Date:  2016-05-21

3.  How we treat mycosis fungoides and Sézary syndrome.

Authors:  Niloufer Khan; Sarah J Noor; Steven Horwitz
Journal:  Clin Adv Hematol Oncol       Date:  2021-09

4.  CD30+ Transformed Mycosis Fungoides Associated with Sweet-like Dermatosis.

Authors:  Florine André; Christa Prins; Michel Gillet; Emmanuella Guenova; Gabriela Blanchard
Journal:  Acta Derm Venereol       Date:  2022-03-31       Impact factor: 3.875

5.  Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.

Authors:  Shiun Chang; Lucia Seminario-Vidal; Kenneth Y Tsai; Pei-Ling Chen; Xiaofei Song; Alvaro de Mingo Pulido; Leticia Tordesillas; Xingzhi Song; Rhianna A Reed; Andrea Harkins; Shannen Whiddon; Jonathan V Nguyen; Carlos Moran Segura; Chaomei Zhang; Sean Yoder; Zena Sayegh; Yun Zhao; Jane L Messina; Carly M Harro; Xiaohui Zhang; José R Conejo-Garcia; Anders Berglund; Lubomir Sokol; Jianhua Zhang; Paulo C Rodriguez; James J Mulé; Andrew P Futreal
Journal:  Cancer Discov       Date:  2022-05-02       Impact factor: 38.272

6.  CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.

Authors:  Hasan H Danish; Thatcher R Heumann; Kyle T Bradley; Jeffrey Switchenko; Natia Esiashvili; Mary Jo Lechowicz; Christopher R Flowers; Mohammad K Khan
Journal:  Dermatol Ther (Heidelb)       Date:  2016-04-16

7.  Oral mycosis fungoides with CD30+ large cell transformation successfully treated with brentuximab vedotin.

Authors:  Clare A Goggins; M Timothy Gocke; Sekwon Jang; Jennifer A DeSimone
Journal:  JAAD Case Rep       Date:  2019-01-30

8.  Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.

Authors:  Cosimo Di Raimondo; Zhen Han; Chingyu Su; Xiwei Wu; Hanjun Qin; James F Sanchez; Yate-Ching Yuan; Xochiquetzal Martinez; Farah Abdulla; Jasmine Zain; Chun-Wei Chen; Steven T Rosen; Christiane Querfeld
Journal:  Cancers (Basel)       Date:  2021-11-22       Impact factor: 6.575

9.  The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study.

Authors:  Alejandro A Gru; Jinah Kim; Melissa Pulitzer; Joan Guitart; Maxime Battistella; Gary S Wood; Lorenzo Cerroni; Werner Kempf; Rein Willemze; Joya Pawade; Christiane Querfeld; Andras Schaffer; Laura Pincus; Michael Tetzlaff; Madeleine Duvic; Julia Scarisbrick; Pierluigi Porcu; Aaron R Mangold; David J DiCaudo; Michi Shinohara; Eric K Hong; Bethany Horton; Youn H Kim
Journal:  Am J Surg Pathol       Date:  2018-06       Impact factor: 6.298

Review 10.  Transformation of Canine Lymphoma/Leukemia to More Aggressive Diseases: Anecdotes or Reality?

Authors:  Stefano Comazzi; Luca Aresu; Laura Marconato
Journal:  Front Vet Sci       Date:  2015-10-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.